EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G)

Yosuke Kito iD, Hisato Kawakami iD, Seiichiro Mitani, Shinichi Nishina, Toshihiko Matsumoto, Takao Tsuzuki, Yudai Shinohara, Hozumi Shimokawa, Ryosuke Kumanishi, Takashi Ohta, Hiroo Katsuya, Takeshi Kawakami und 7 weitere

The Oncologist · 2024

DOI: 10.1093/oncolo/oyad296 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, 2024. Verfasst von Yosuke Kito und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan. Hauptthemen laut MEDLINE: Colorectal Neoplasms, Frontotemporal Dementia, Colonic Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 23 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Taiho Pharmaceutical Co., Ltd..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Trifluridine/tipiracil (FTD/TPI) plus bevacizumab has shown clinical benefit for metastatic colorectal cancer (mCRC) refractory to standard therapy. However, few data have been available for patients with pretreated mCRC who are intolerant of intensive therapy (vulnerable).

Methods

We performed a multicenter retrospective study (WJOG14520G; TWILIGHT) of FTD/TPI plus bevacizumab for vulnerable patients with pretreated mCRC. Eligibility criteria included previous chemotherapy (although patients treated with all key cytotoxic agents, a fluoropyrimidine, oxaliplatin, and irinotecan, were excluded) and intolerance of full-dose combination therapy with oxaliplatin or irinotecan at the start of FTD/TPI plus bevacizumab.

Results

The median age of 93 evaluable patients was 79 years (range, 21-90). Intolerance of intensive therapy was attributable to an older age in 60 (65%) patients, serious concomitant disease in 24 (26%) patients, and a poor performance status in 19 (20%) patients. FTD/TPI plus bevacizumab was administered as second-line treatment in 74 (80%) patients and as third- or fourth-line treatment in 19 (20%) patients. The objective response rate was 4.9% (95% confidence interval [CI], 1.4%-12.2%), and the disease control rate was 67.9% (95% CI, 56.6%-77.8%). With a median follow-up time of 21.6 months, median overall survival and progression-free survival were 18.6 months (95% CI, 12.1-23.2) and 6.3 months (95% CI, 5.0-8.3), respectively. Neutropenia of grade ≥3 developed in 50 (54%) patients, whereas 2 (2%) patients experienced febrile neutropenia, and no treatment-related death was observed.

Conclusion

Our data show the potential efficacy and acceptable safety profile of FTD/TPI plus bevacizumab for vulnerable patients with pretreated mCRC.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colorectal NeoplasmsFrontotemporal DementiaColonic NeoplasmsRectal NeoplasmsPyrrolidinesThymineHumansYoung AdultAdultMiddle AgedAgedAged, 80 and overBevacizumabRetrospective StudiesUracilOxaliplatinTrifluridineIrinotecanAntineoplastic Combined Chemotherapy ProtocolsDrug Combinations

Stichwörter der Autor:innen

bevacizumabintensive therapymetastatic colorectal cancertrifluridine/tipiracilvulnerable patients

Substanzen

tipiracilBevacizumabUracilOxaliplatinTrifluridineIrinotecanDrug CombinationsPyrrolidinesThymine

Autor:innen und Institutionen

  • Department of Medical Oncology, Ishikawa Prefectural Central Hospital, Ishikawa, Japan.
  • Department of Medical Oncology, Kindai University Faculty of Medicine, Osaka, Japan.
  • Department of Medical Oncology, Kurashiki Central Hospital, Okayama, Japan.
  • Department of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan.
  • Department of Internal Medicine, Japanese Red Cross Society Himeji Hospital, Hyogo, Japan.
  • Department of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan.

ORCID-Profile: Yosuke Kito, Hisato Kawakami

Förderung

  • Taiho Pharmaceutical Co., Ltd.

Zitieren

APA

Kito, Y., Kawakami, H., Mitani, S., Nishina, S., Matsumoto, T., Tsuzuki, T., Shinohara, Y., Shimokawa, H., Kumanishi, R., Ohta, T., Katsuya, H., Kawakami, T., Nishina, T., Hasegawa, H., Akiyoshi, K., Chiba, Y., Yamazaki, K., Hironaka, S., & Muro, K. (2024). Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). The Oncologist. https://doi.org/10.1093/oncolo/oyad296

Vancouver

Kito Y, Kawakami H, Mitani S, Nishina S, Matsumoto T, Tsuzuki T, et al. Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G). The Oncologist. 2024. doi:10.1093/oncolo/oyad296

BibTeX
@article{Kito2024,
  author = {Kito, Yosuke and Kawakami, Hisato and Mitani, Seiichiro and Nishina, Shinichi and Matsumoto, Toshihiko and Tsuzuki, Takao and Shinohara, Yudai and Shimokawa, Hozumi and Kumanishi, Ryosuke and Ohta, Takashi and Katsuya, Hiroo and Kawakami, Takeshi and Nishina, Tomohiro and Hasegawa, Hiroko and Akiyoshi, Kohei and Chiba, Yasutaka and Yamazaki, Kentaro and Hironaka, Shuichi and Muro, Kei},
  title = {Trifluridine/Tipiracil Plus Bevacizumab for Vulnerable Patients With Pretreated Metastatic Colorectal Cancer: A Retrospective Study (WJOG14520G)},
  journal = {The Oncologist},
  year = {2024},
  doi = {10.1093/oncolo/oyad296}
}
Kostenlos starten →